Central nervous system effects of the histamine‐3 receptor antagonist CEP‐26401, in comparison with modafinil and donepezil, after a single dose in a cross‐over study in healthy volunteers-Reference-Cited by-同舟云学术

Central nervous system effects of the histamine‐3 receptor antagonist CEP‐26401, in comparison with modafinil and donepezil, after a single dose in a cross‐over study in healthy volunteers

Published:2019-03-14 Issue:5 Volume:85 Page:970-985
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Baakman Anne C.¹^ORCID,Zuiker Rob¹,Gerven Joop M.A.¹,Gross Nicholas²,Yang Ronghua²,Fetell Michael²,Gershon Ari³⁴,Gilgun‐Sherki Yossi⁵,Hellriegel Edward⁶,Spiegelstein Ofer⁷

Affiliation:

1. Centre for Human Drug Research Leiden Netherlands

2. Research and Development Teva Pharmaceuticals Frazer Philadelphia USA

3. Global Patient Safety and Pharmacovigilance, Teva Pharmaceuticals Petah Tikva Israel

4. Formerly Global Patient Safety and Pharmacovigilance, Teva Pharmaceuticals Petah Tikva Israel

5. Formerly Research and Development Teva Pharmaceuticals Netanya Israel

6. Research and Development Teva Pharmaceuticals West Chester Pennsylvania USA

7. Research and Development Teva Pharmaceuticals Netanya Israel

Funder

Teva Pharmaceutical Industries

Publisher

Wiley